HBV/HCV/HIV/CMV serology + latent TB testing mandatory pre-induction; rituximab-containin...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-B-ALL-INFECTION-SCREENING`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-B-ALL`
Sources	`SRC-ESMO-DLBCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	HBV/HCV/HIV/CMV serology + latent TB testing mandatory pre-induction; rituximab-containing regimens (CD20+ B-ALL) require HBV prophylaxis.
Clinical direction	investigate
Category	infection-screening

Trigger Logic

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hcv",
      "value": "positive"
    },
    {
      "finding": "hiv_serology",
      "value": "positive"
    },
    {
      "finding": "tb_latent",
      "value": "positive"
    }
  ],
  "type": "biomarker"
}

Notes

Cross-disease HBV reactivation handled by RF-UNIVERSAL-HBV-REACTIVATION-RISK. CMV monitoring critical given prolonged immunosuppression of B-ALL induction/consolidation.

Used By

Algorithms

ALGO-B-ALL-2L - ALGO-B-ALL-2L

Indications

IND-B-ALL-2L-INOTUZUMAB - IND-B-ALL-2L-INOTUZUMAB
IND-B-ALL-3L-TISAGENLECLEUCEL - IND-B-ALL-3L-TISAGENLECLEUCEL
IND-B-ALL-BLINATUMOMAB-MRD-OR-RR - IND-B-ALL-BLINATUMOMAB-MRD-OR-RR
IND-B-ALL-POST-CONSOLIDATION-POMP-MAINTENANCE - IND-B-ALL-POST-CONSOLIDATION-POMP-MAINTENANCE